Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 0.00% is 100% below its 5-year average of 28.57%, near the low end of its 5-year range (0.00%–100.00%).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
28.57%
GROSS MARGIN AVG 10Y
62.99%
GROSS MARGIN AVG 15Y
73.48%
GROSS MARGIN AVG 20Y
63.13%
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
-100.00%
CURRENT VS 10Y AVG
-100.00%
CURRENT VS 15Y AVG
-100.00%
CURRENT VS 20Y AVG
-100.00%
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Summit Therapeutics Inc.
Market Cap
$13.81B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
28.57%
Market Cap
$14.04B
Gross Margin
90.18%
TTM Avg
86.45%
3Y Avg
83.14%
5Y Avg
81.21%
Market Cap
$13.11B
Gross Margin
93.35%
TTM Avg
96.31%
3Y Avg
90.48%
5Y Avg
92.91%
Market Cap
$14.54B
Gross Margin
84.67%
TTM Avg
88.63%
3Y Avg
87.78%
5Y Avg
88.43%
Market Cap
$13.01B
Gross Margin
78.18%
TTM Avg
81.22%
3Y Avg
79.53%
5Y Avg
80.59%
Market Cap
$14.63B
Gross Margin
97.97%
TTM Avg
98.37%
3Y Avg
98.27%
5Y Avg
98.48%
Market Cap
$14.69B
Gross Margin
32.24%
TTM Avg
31.70%
3Y Avg
34.15%
5Y Avg
35.17%
Market Cap
$12.93B
Gross Margin
98.30%
TTM Avg
98.34%
3Y Avg
98.50%
5Y Avg
98.50%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | $13.81B | 0.00% | 0.00% | 0.00% | 28.57% |
| Ascendis Pharma A/S (ASND)vs › | $14.04B | 90.18% | 86.45% | 83.14% | 81.21% |
| BridgeBio Pharma, Inc. (BBIO)vs › | $13.11B | 93.35% | 96.31% | 90.48% | 92.91% |
| Jazz Pharmaceuticals plc (JAZZ)vs › | $14.54B | 84.67% | 88.63% | 87.78% | 88.43% |
| Halozyme Therapeutics, Inc. (HALO)vs › | $13.01B | 78.18% | 81.22% | 79.53% | 80.59% |
| Neurocrine Biosciences, Inc. (NBIX)vs › | $14.63B | 97.97% | 98.37% | 98.27% | 98.48% |
| Exelixis, Inc. (EXEL)vs › | $14.66B | 96.48% | 96.44% | 96.31% | 96.33% |
| Charles River Laboratories International, Inc. (CRL)vs › | $14.69B | 32.24% | 31.70% | 34.15% | 35.17% |
| Corcept Therapeutics Incorporated (CORT)vs › | $12.93B | 98.30% | 98.34% | 98.50% | 98.50% |
| Tempus AI, Inc. (TEM)vs › | $12.61B | 63.98% | 58.85% | 53.03% | 43.30% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 100.00% |
| 2022-06-30 | 100.00% |
| 2022-03-31 | 100.00% |
| 2021-12-31 | 100.00% |
| 2021-09-30 | 100.00% |
| 2021-06-30 | 100.00% |
| 2021-03-31 | 100.00% |
| 2020-12-31 | 100.00% |
| 2020-09-30 | 100.00% |
| 2020-06-30 | 100.00% |
| 2020-03-31 | 100.00% |
| 2019-12-31 | 100.00% |
| 2019-10-31 | 100.00% |
| 2019-07-31 | 100.00% |
| 2019-04-30 | 100.00% |
| 2019-01-31 | 82.46% |
| 2018-10-31 | 100.00% |
| 2018-07-31 | 100.00% |
| 2018-04-30 | 100.00% |
| 2018-01-31 | 100.00% |
| 2017-10-31 | 100.00% |
| 2017-07-31 | 100.00% |
| 2017-04-30 | 100.00% |
| 2017-01-31 | 100.00% |
| 2016-10-31 | 100.00% |
| 2016-07-31 | 100.00% |
| 2016-04-30 | 100.00% |
| 2016-01-31 | 100.00% |
| 2015-10-31 | 100.00% |
| 2015-07-31 | 100.00% |
| 2015-04-30 | 100.00% |
| 2015-01-31 | 100.00% |
| 2014-10-31 | 100.00% |
| 2014-07-31 | 100.00% |
| 2014-04-30 | 100.00% |
| 2014-01-31 | 100.00% |
| 2013-10-31 | 100.00% |
| 2013-07-31 | 100.00% |
| 2013-04-30 | 100.00% |
| 2013-01-31 | 100.00% |
| 2012-10-31 | 100.00% |
| 2012-07-31 | 100.00% |
| 2012-04-30 | 100.00% |
| 2012-01-31 | 100.00% |
| 2011-10-31 | 100.00% |
| 2011-07-31 | 0.00% |
| 2011-01-31 | 0.00% |
| 2010-07-31 | 0.00% |
| 2010-01-31 | 0.00% |
| 2009-07-31 | 0.00% |
| 2009-01-31 | 0.00% |
| 2008-07-31 | 0.00% |
| 2008-01-31 | 0.00% |
| 2007-07-31 | 0.00% |
| 2007-01-31 | 0.00% |
| 2006-07-31 | 0.00% |
| 2006-01-31 | 0.00% |
| 2005-07-31 | 0.00% |
| 2005-01-31 | 0.00% |
| 2004-07-31 | 0.00% |
